Takeda Pharmaceutical/$TAK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Ticker

$TAK

Primary listing

NYSE

Industry

Pharmaceuticals

Headquarters

Tokyo, Japan

Employees

47,455

ISIN

US8740602052

TAK Metrics

BasicAdvanced
$47B
32.21
$0.46
0.26
$0.54
3.76%

What the Analysts think about TAK

Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.

Bulls say / Bears say

Takeda reported a 13.4% year-over-year revenue increase, reaching JPY 2,384 billion, driven by strong performance in Plasma-Derived Therapies, Oncology, and Vaccines. (TipRanks)
The company has entered into multiple licensing agreements with Indian pharmaceutical firms to market Vonoprazan, expanding its gastrointestinal product portfolio in the Indian market. (The Economic Times)
Takeda's strategic partnership with Biological E Ltd aims to manufacture up to 100 million doses of its dengue vaccine annually, enhancing its presence in the global vaccine market. (Business Standard)
Takeda announced layoffs of 641 employees in Massachusetts as part of a restructuring plan, indicating potential operational challenges. (Wikipedia)
The company is withdrawing its lung cancer drug, Exkivity, from the U.S. market after a failed late-stage study, which may impact its oncology portfolio. (Wikipedia)
Takeda's Q3 2025 profits slid 38%, trailing analyst estimates, suggesting financial performance concerns. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TAK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TAK

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs